Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  López Gómez, Carlos ^a   Pino Ángeles, Almudena ^b,e   Órpez Zafra, Teresa ^a,f   Pinto Medel, María Jesús ^a,f   Oliver Martos, Begoña ^a,f   Ortega Pinazo, Jesús ^a   Arnáiz, Carlos ^a   Guijarro Castro, Cristina ^c,f   Varadé, Jezabel ^d,f   Álvarez Lafuente, Roberto ^d,f   Urcelay, Elena ^d,f   Sánchez Jiménez, Francisca ^b,e   Fernández, Óscar ^a,f   Leyva, Laura ^a,f  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f Red Española de Esclerosis Múltiple REEM RD 07 0060   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BETA INTERFERON; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GLATIRAMER; GLUTAMIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ADOLESCENT; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; ONSET AGE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRAIL GENE; TRAILR 1 GENE; TRAILR 2 GENE; TRAILR 3 GENE; TRAILR 4 GENE;

ADOLESCENT; ADULT; AGED; BINDING SITES; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MODELS, MOLECULAR; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 84876911065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062540     Document Type: Article

References (51)

1. McKeage K, (2008) Interferon-beta-1b: in newly emerging multiple sclerosis. CNS Drugs 22: 787-792.
2. Doggrell SA, (2010) Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin Pharmacother 11: 1225-1230.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504.
4. Fernandez O, Arbizu T, Izquierdo G, Martinez-Yelamos A, Gata JM, et al. (2003) Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study. Acta Neurol Scand 107: 7-11.
5. Rio J, Nos C, Tintore M, Tellez N, Galan I, et al. (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59: 344-352.
6. Villoslada P, Barcellos LF, Rio J, Begovich AB, Tintore M, et al. (2002) The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 130: 194-201.
7. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, et al. (2003) Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 4: 147-152.
8. Wergeland S, Beiske A, Nyland H, Hovdal H, Jensen D, et al. (2005) IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 12: 171-175.
9. Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, et al. (2005) IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 163: 165-171.
10. Fernandez O, Fernandez V, Mayorga C, Guerrero M, Leon A, et al. (2005) HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand 112: 391-394.
11. Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, et al. (2005) Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 78: 635-646.
12. Weinstock-Guttman B, Tamano-Blanco M, Bhasi K, Zivadinov R, Ramanathan M, (2007) Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol 182: 236-239.
13. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, et al. (2008) Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 65: 337-344.
14. O'Doherty C, Favorov A, Heggarty S, Graham C, Favorova O, et al. (2009) Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics 10: 1177-1186.
15. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, et al. (2009) Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 66: 972-978.
16. Wiley SR, (1995) Schooley K, Smolak PJ, Din WS, Huang CP, et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
17. Kimberley FC, Screaton GR, (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14: 359-372.
18. Aktas O, Schulze-Topphoff U, Zipp F, (2007) The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci 12: 2912-2921.
19. Falschlehner C, Schaefer U, Walczak H, (2009) Following TRAIL's path in the immune system. Immunology 127: 145-154.
20. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, et al. (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189: 1451-1460.
21. Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dorr J, et al. (2005) Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult Scler 11: 652-657.
22. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, et al. (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31: 3138-3146.
23. Zula JA, Green HC, Ransohoff RM, Rudick RA, Stark GR, et al. (2011) The role of cell type-specific responses in IFN-beta therapy of multiple sclerosis. Proc Natl Acad Sci U S A 108: 19689-19694.
24. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, et al. (2003) TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361: 2036-2043.
25. Lopez-Gomez C, Fernandez O, Garcia-Leon JA, Pinto-Medel MJ, Oliver-Martos B, et al. (2011) TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis. PLoS One 6: e21766.
26. Hebb AL, Moore CS, Bhan V, Robertson GS, (2010) Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes. Autoimmune Dis 2011: 485752.
27. Barblu L, Herbeuval JP, (2012) Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4 T cells and apoptosis. PLoS One 7: e32874.
28. Van Weyenbergh J, Wietzerbin J, Rouillard D, Barral-Netto M, Liblau R, (2001) Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death. J Leukoc Biol 70: 745-748.
29. Lunemann JD, Waiczies S, Ehrlich S, Wendling U, Seeger B, et al. (2002) Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168: 4881-4888.
30. Ikeda T, Hirata S, Fukushima S, Matsunaga Y, Ito T, et al. (2010) Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol 185: 5259-5267.
31. Frank B, Hemminki K, Shanmugam KS, Meindl A, Klaes R, et al. (2005) Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis 26: 1975-1977.
32. Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, et al. (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 15: 2002-2005.
33. Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, et al. (2006) Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 118: 1831-1835.
34. Chen B, Liu S, Wang XL, Xu W, Li Y, et al. (2009) TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer 45: 2598-2605.
35. Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, et al. (2008) The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 68: 264-268.
36. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K, (2002) TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125: 2469-2480.
37. Valley CC, Lewis AK, Mudaliar DJ, Perlmutter JD, Braun AR, et al. (2012) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem 287: 21265-21278.
38. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, et al. (2005) TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 167: 170-174.
39. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18: 767-778.
40. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
41. WHO Expert Committee on Biological Standardization (1985) Thirty-fifth report. World Health Organ Tech Rep Ser 725: 1-140.
42. Oliver B, Orpez T, Mayorga C, Pinto-Medel MJ, Leyva L, et al. (2009) Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection. J Immunol Methods 351: 41-45.
43. Kawade Y, Finter N, Grossberg SE, (2003) Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 278: 127-144.
44. Chomczynski P, Sacchi N, (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
45. Rozen S, Skaletsky H, (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
46. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, et al. (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23: 644-645.
47. Wigginton JE, Cutler DJ, Abecasis GR, (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887-893.
48. Notredame C, Higgins DG, Heringa J, (2000) T-Coffee: A novel method for fast and accurate multiple sequence alignment. J Mol Biol 302: 205-217.
49. Jorgensen W, Chandrasekhar J, Madura J, Impey R, Klein M, (1983) Comparison of simple potential functions for simulating water. J Chem Phys 79: 926-935.
50. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An N{dot operator}log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
51. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, et al. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24: 1999-2012.